IP Library › Granted Patent US 12,414,926
Granted Patent B2
US 12,414,926 · App. 18/500,175 · Granted Sep 16, 2025

Topical fertility promoting product and manufacturing method

Inventor: Wendy Strgar (Eugene, OR)
Assignee: VAGINAL BIOME SCIENCE, INC.
A61K31/191A61K9/00A61K9/0034A61K9/06A61K47/02A61K47/12A61K47/36A61K47/38G01N33/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,926
App. No.
18/500,175
Granted
Sep 16, 2025
Kind
B2
Abstract

Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.

Claims (35)

1. A topical substance for promoting fertility comprising:

a solvent;

a plurality of salts dissolved in the solvent such that an osmolality of the topical substance matches an osmolality of healthy vaginal secretions; and

up to 2% by weight of lactic acid,

wherein a chance of conception of a subject that has been administered an effective amount of the topical substance is higher than the chance of conception of a subject that has not been administered the topical substance.

2. The topical substance according to claim 1 ,

wherein the topical substance is formulated such that a pH of a vaginal fluid becomes from 3 to 5 when the effective amount of the topical substance is applied to the vagina of the subject, and

the pH of the vaginal fluid becomes from 6 to 8 when the effective amount of the topical substance is applied to the vagina of the subject and is further mixed with semen.

3. The topical substance according to claim 1 ,

wherein the topical substance has a pH of from 3 to 6, and a buffering capacity such that adding from 5 to 20 millimoles of NaOH to 1 gram of the substance increases the pH by at least 1.

4. The topical substance according to claim 1 ,

wherein the amount of lactic acid is up to 0.05% by weight.

5. The topical substance according to claim 1 ,

wherein the amount of lactic acid is from 0.2% to 2% by weight.

6. The topical substance according to claim 1 ,

wherein the topical substance has an osmolality of from 100 mOsm/kg to 500 mOsm/kg.

7. The topical substance according to claim 1 ,

wherein the plurality of salts dissolved in the solvent comprises, by 100% weight of the topical substance:

up to 0.5% by weight of a potassium salt;

up to 1.5% by weight of a sodium salt; and

up to 0.5% by weight of a calcium salt.

8. The topical substance according to claim 7 ,

wherein the plurality of salts further comprises up to 0.5% by weight of magnesium salt by 100% weight of the topical substance.

9. The topical substance according to claim 8 ,

wherein the plurality of salts dissolved in the solvent comprises, by 100% weight of the topical substance:

from 0.15% to 0.35% of a potassium salt;

from 0.3% to 1.0% of a sodium salt;

from 0.005% to 0.12% of a calcium salt; and

from 0.03% to 0.07% of a magnesium salt.

10. The topical substance according to claim 1 ,

wherein the substance is free from alkaline ingredients.

11. The topical substance according to claim 1 ,

wherein the topical substance is non-toxic to a human vagina.

12. The topical substance according to claim 1 ,

wherein a continued use of the topical substance does not make a vaginal environment of a subject that has been administered the topical substance more prone to disease or damage compared with a vaginal environment of a subject that has not been administered the topical substance.

Continuity (7)
Division 17209252 · Mar 23, 2021
Continuation 16191292 · Nov 14, 2018
Continuation In Part 15691645 · Aug 30, 2017
Continuation In Part 15294340 · Oct 14, 2016
Continuation 14636035 · Mar 2, 2015
Provisional Application 62094769 · Dec 19, 2014
Related Publication 20240058286A1 · Feb 22, 2024
References Cited (43)
US 5466463A · Ford · 1995 [cited by applicant]
US 5765579A · Heiler et al. · 1998 [cited by applicant]
US 5778886A · Shihata · 1998 [cited by applicant]
US 6045786A · Cone et al. · 2000 [cited by applicant]
US 6892732B2 · Wang et al. · 2005 [cited by applicant]
US 8367098B2 · Maguire et al. · 2013 [cited by applicant]
US 9470676B2 · Strgar · 2016 [cited by examiner]
US 10195169B2 · Strgar · 2019 [cited by examiner]
US 10952979B2 · Strgar · 2021 [cited by examiner]
US 20040132690A1 · Carmella et al. · 2004 [cited by applicant]
US 20090105314A1 · Ii et al. · 2009 [cited by applicant]
US 20120195961A1 · Kritikou · 2012 [cited by applicant]
US 20130039944A1 · Iadonato et al. · 2013 [cited by applicant]
US 20140147520A1 · Gupta et al. · 2014 [cited by applicant]
CN 1113150 · 1995 [cited by applicant]
CN 101559036 · 2009 [cited by applicant]
CN 101773513 · 2010 [cited by applicant]
CN 102512338 · 2012 [cited by applicant]
CN 102266283 · 2012 [cited by applicant]
EP 1582186 · 2005 [cited by applicant]
EP 2018872 · 2009 [cited by applicant]
JP 03264520 · 1991 [cited by applicant]
JP 101430 · 1998 [cited by applicant]
KR 20090054777 · 2009 [cited by applicant]
WO 2001095951 · 2001 [cited by applicant]
WO 2006075236 · 2006 [cited by applicant]
WO 2014152154 · 2014 [cited by applicant]
Aroutcheva, et al., “Defense Factors of Vaginal Lactobacilli,” Am. J. Obstet Gynecol, 2001, vol. 185(2), pp. 375-379. [cited by applicant]
Ayehunie, et al., “Hyperosmolal Vaginal Lubricants Markedly Reduce Epithelial Barrier Properties in a Three-Dimensional Vaginal Epithelium Model,” Toxicology Reports, 2018, vol. 5, pp. 134-140. [cited by applicant]
Balance Activ Vaginal Gel (7x5ml Tubes) Product Information 2013, https:www.expresschemist.co.uk/balance_activ_vaginal_gel.html, pp. 2. [cited by applicant]
Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 18. [cited by applicant]
Gynofit Gel with Lactic Acid, 2010, http://www.gynofit.com/milchsaeure-vaginalgel-en.html, pp. 2. [cited by applicant]
Gynofit Lactic Acid Vaginal Gel 5ml N6 Product Information 2013, http://ww.efarma.It, pp. 3. [cited by applicant]
Manjakani Plus Feminine Wash with Kacip Fatimah, Product Information 2013 https://www.hervsforlove.com, pp. 2. [cited by applicant]
Moench, et al., “Microbicide Excipients Can Greatly Increase Susceptibility to Genital Herpes Transmission in the Mouse,” BMC Infect. Dis., 2010, vol. 10 (331), pp. 9. [cited by applicant]
Natural Ecological Lubricant, Organic Products without Intermediaries, Product Information 2013, https://www.productosecologicossinintermediarios.es, pp. 3. [cited by applicant]
Owen, et al., “A Review of the Physical and Chemical Properties of Human semen and the Formulation of a Semen Simulant,” J. Androl., 2005, vol. 26 (4), pp. 459-469. [cited by applicant]
Owen, et al., “A Vaginal Fluid Simulant,” Contraception, 1999, vol. 59 (2), pp. 91-95. [cited by applicant]
Pre-Seed—Vaginal Lubricant, Product Information 2013, https://www.amazon.co.uk, pp. 6. [cited by applicant]
Rastogi, et al., “Engineering and Characterization of Simplified Vaginal and Seminal Fluid Simulants,” Contraception, 2016, vol. 93 (4), pp. 337-346. [cited by applicant]
Tien, et al., “In Vitro and in Vivo Characterization of a Potential Universal Placebo Designed for use in Vaginal Microbicide Clinical Trials,” AIDS Res. Hum. Retroviruses, 2005, vol. 21 (10), pp. 845-853. [cited by applicant]
Vegan Spermicide Alternative, Product Information 2013, https://vegan-love.com, pp. 7. [cited by applicant]
Yes Intimate Lubricants, The Natural Skincare Company, Product Information 2013, https://www.thenaturalskincarecompany.co.k, pp. 4. [cited by applicant]